# Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC

> **NCT06810609** · PHASE2 · RECRUITING · sponsor: **University Hospital, Bonn** · enrollment: 176 (estimated)

## Conditions studied

- Lung Cancer Non-Small Cell Cancer (NSCLC)

## Interventions

- **PROCEDURE:** surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
- **RADIATION:** Chemoradiotherapy
- **DRUG:** Immunotherapy

## Key facts

- **NCT ID:** NCT06810609
- **Lead sponsor:** University Hospital, Bonn
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-20
- **Primary completion:** 2029-12-31
- **Final completion:** 2030-09-30
- **Target enrollment:** 176 (ESTIMATED)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06810609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06810609, "Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06810609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*